Anti-Nausea Medication Guidelines

Chemotherapy-Induced Nausea

The American Society of Clinical Oncology recommends a combination of a 5-HT3 receptor antagonist (ondansetron, granisetron, or palonosetron) plus dexamethasone plus aprepitant for chemotherapy-induced nausea and vomiting, representing the most effective regimen 1, 2, 3
The National Comprehensive Cancer Network suggests that triple therapy with a 5-HT3 antagonist + Dexamethasone + Aprepitant provides superior control compared to any two-drug combination for highly emetogenic chemotherapy 4, 3
Ondansetron 16-24 mg orally once daily or granisetron 2 mg orally once daily or palonosetron 0.25 mg IV is recommended for chemotherapy-induced nausea and vomiting 1, 2
Dexamethasone 20 mg IV on day 1, reduced to 10 mg when combined with aprepitant due to drug interactions, is recommended for chemotherapy-induced nausea and vomiting 1, 2
Aprepitant 125 mg orally on day 1, then 80 mg on days 2-3, is recommended for chemotherapy-induced nausea and vomiting 1, 2, 3

The American Gastroenterological Association recommends metoclopramide 10-20 mg orally/IV 3-4 times daily for general nausea, which works through dopamine blockade and prokinetic effects 1, 2, 5
Prochlorperazine 10-20 mg orally or 5-10 mg IV 3-4 times daily is a highly effective dopamine antagonist for general nausea 1, 2, 5

The National Comprehensive Cancer Network recommends 5-HT3 antagonists, such as ondansetron or granisetron, with or without dexamethasone for upper abdominal radiation 4
For total body irradiation, the National Comprehensive Cancer Network suggests using ondansetron or granisetron plus dexamethasone 4

The American Society of Clinical Oncology recommends adding dopamine antagonists, such as metoclopramide or prochlorperazine, to existing 5-HT3 antagonist and corticosteroid regimen for refractory or breakthrough nausea 1, 2
Haloperidol 0.5-2 mg IV/PO every 6-8 hours can be considered for severe refractory cases 5

The American Society of Clinical Oncology recommends preventing acute and delayed nausea with optimal antiemetic prophylaxis as the best treatment for anticipatory nausea 6, 3
Lorazepam 0.5-2 mg orally/IV every 4-6 hours can be added, though efficacy decreases with repeated chemotherapy cycles 4, 6

The American Society of Clinical Oncology recommends never using 5-HT3 antagonists in patients with serotonin syndrome, as they can precipitate or worsen the condition 5
Aprepitant is metabolized via CYP3A4 and reduces corticosteroid doses by 50% when used in combination 1, 2

The American Gastroenterological Association recommends starting with metoclopramide 10-20 mg IV or prochlorperazine 10 mg IV for acute severe nausea without known cause 1, 2, 5
If inadequate response within 30-60 minutes, adding ondansetron 8 mg IV is recommended 7
Dexamethasone 4-8 mg IV can be considered as adjunctive therapy 1, 5

The American Society of Clinical Oncology recommends a triple combination therapy of an NK₁ receptor antagonist + 5-HT₃ receptor antagonist + dexamethasone for highly emetogenic situations, achieving 70-86% complete control of vomiting 8
The National Comprehensive Cancer Network suggests dosing for triple therapy as aprepitant 125 mg PO day 1, then 80 mg PO days 2-3, plus a 5-HT₃ antagonist day 1, and dexamethasone 12 mg PO/IV days 1-4 9, 10, 11

Palonosetron, a 5-HT₃ antagonist, achieves 56.8% delayed phase control when administered as 0.25 mg IV day 1, and demonstrates superior delayed phase control compared to other 5-HT₃ antagonists 8, 12, 13
Granisetron has equivalent efficacy to ondansetron for acute emesis, with a dosing regimen of 2 mg PO or 1 mg IV or 0.01 mg/kg IV (max 1 mg) 8, 9, 11
Ondansetron has equivalent efficacy to granisetron and dolasetron, with a dosing regimen of 8-16 mg PO or 8 mg IV (max 32 mg/day) 8, 9, 11, 13

Prochlorperazine is a highly effective dopamine antagonist, with a dosing regimen of 10 mg PO/IV every 4-6 hours, but carries a risk of akathisia and extrapyramidal symptoms 9
Metoclopramide has prokinetic effects beneficial for gastroparesis-related nausea, with a dosing regimen of 10-20 mg PO/IV 3-4 times daily, but also carries a risk of akathisia 9

Dexamethasone enhances efficacy when added to 5-HT₃ antagonists, with a dosing regimen of 4-20 mg PO/IV depending on indication, and is effective as monotherapy for low emetogenic risk 9, 11, 13

Promethazine is suitable when sedation is desirable, with a dosing regimen of 12.5-25 mg PO/IV every 4 hours, but is more sedating than other agents and carries a risk of vascular damage with IV administration 9

For chemotherapy-induced nausea with high emetogenic risk, the National Comprehensive Cancer Network recommends triple therapy: NK₁ antagonist + palonosetron + dexamethasone 8, 12
For breakthrough or refractory nausea, adding an agent from a different drug class is recommended 9